CAPRICOR THERAPEUTICS, INC. (CAPR)

Current Report Filed: 2026-05-07

Key Insights

Capricor filed a lawsuit against Nippon Shinyaku and its U.S. subsidiary NS Pharma alleging fundamental pricing flaws and material breach of the January 2022 Commercialization and Distribution Agreement for Deramiocel, seeking rescission and the right to distribute directly or through alternative distributors.
The company claims NS failed to adequately prepare for commercial launch of Deramiocel (a DMD treatment), suggesting potential delays or inadequate commercialization efforts that could impact revenue realization and patient access.
This legal action represents a significant dispute over a key commercial partnership, with potential outcomes including loss of the distribution agreement, recovery of distribution rights, and preliminary injunctive relief, creating material uncertainty around the product's U.S. commercialization strategy.

Insider Trading Filed: 2026-04-03

Key Insights

The reporting person, Karimah Es Sabar, exercised 7,529 stock options and immediately sold the same number of shares, indicating a possible liquidity event or portfolio rebalancing.
The stock sale was made pursuant to a 10b5-1 trading plan, suggesting a predetermined and systematic approach to the transaction.
The reporting person still holds 161 stock options, suggesting ongoing engagement and alignment with the company's long-term performance.

Insider Trading Filed: 2026-03-27

Key Insights

The reporting person, Karen Krasney, is an Executive Vice President and General Counsel at Capricor Therapeutics, Inc. (CAPR), indicating a key insider transaction.
Krasney exercised 2,500 stock options at an exercise price of $1.39 per share, increasing her direct beneficial ownership in CAPR to 30,547 shares.
The stock options were previously granted in 2017 and were adjusted to reflect a 1-for-10 reverse split and a share reprice, suggesting a long-term incentive alignment with the company's performance.

Annual Report Filed: 2026-03-17

Key Insights

The company executed a September 2025 At-The-Market (ATM) stock offering program, raising additional capital to fund operations and research and development activities.
The company completed a December 2025 underwritten public offering, further strengthening its balance sheet and financial position.
The company has established a commercialization and distribution agreement with Nippon Shinyaku Co., Ltd. for the United States and Japan, which provides potential revenue streams and expanded market access.

Current Report Filed: 2026-03-12

Key Insights

Capricor Therapeutics reported its Q4 2025 and full year 2025 financial results, which provide an update on the company's financial performance and operational progress.
The company's cash position and funding levels appear sufficient to support its ongoing clinical development programs and operations, which is a positive sign for investors.
There were no significant leadership changes or material agreements announced in this 8-K filing, indicating a relatively stable period for the company.

Current Report Filed: 2026-03-10

Key Insights

The FDA has lifted the previously issued Complete Response Letter and resumed review of Capricor's Biologics License Application for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy cardiomyopathy. This is a positive development as it moves the drug candidate closer to potential approval.
The BLA submission has been classified as a Class 2 resubmission, indicating that the FDA considers the application to be a relatively straightforward review process with a target action date of August 22, 2026.
Capricor provided forward-looking statements cautioning investors about the risks and uncertainties associated with the BLA review process, including known and unknown factors that could impact the company's actual results.

Insider Trading Filed: 2026-01-07

Key Insights

The reporting person, Frank Litvack, was granted a stock option to acquire 50,000 shares of Capricor Therapeutics, Inc. common stock at an exercise price of $24.81 per share. This indicates Litvack is taking on a larger role or position with the company.
The stock option vests over a 12-month period, with 1/12th of the shares vesting on the first day of each month starting in February 2026. This suggests Litvack is being incentivized to remain with the company for the long-term.
The stock option can be exercised early, with any unvested shares being subject to a repurchase option by the company if Litvack's service is terminated prior to vesting. This provides Litvack with flexibility in managing his equity position.

Insider Trading Filed: 2026-01-07

Key Insights

Insider George W. Dunbar Jr. has been granted a stock option to purchase 15,500 shares of Capricor Therapeutics, Inc. (CAPR) common stock, vesting over the course of 2026.
The option has an exercise price of $24.81 per share and a 10-year term, expiring on January 5, 2036.
The insider purchase suggests confidence in the company's future prospects and aligns Dunbar's interests with those of shareholders.

Insider Trading Filed: 2026-01-07

Key Insights

David B. Musket, a director of Capricor Therapeutics, Inc. (CAPR), was granted a stock option to purchase 15,500 shares of the company's common stock on January 5, 2026, with the shares vesting over the course of the year.
The option has an exercise price of $24.81 per share and will expire on January 5, 2036, indicating the company's intention to incentivize and retain Musket's board service.
The early exercise feature of the option allows Musket to purchase the shares before they vest, subject to a repurchase option by the company if his service terminates prior to vesting.

Insider Trading Filed: 2026-01-07

Key Insights

Mike Kelliher, a director of Capricor Therapeutics, has been granted 15,500 stock options with an exercise price of $24.81, vesting over the course of 2026.
The stock options are subject to early exercise, allowing Kelliher to purchase shares before they vest and have them treated as restricted stock.
This insider transaction suggests Kelliher's confidence in Capricor's future and aligns his interests with those of shareholders.

Insider Trading Filed: 2026-01-07

Key Insights

The CEO, Linda Marban, acquired a significant number of stock options and restricted stock units, indicating her confidence in the company's future performance.
A portion of the stock options granted to the CEO are tied to the FDA approval of the company's lead product candidate, Deramiocel, demonstrating the importance of this regulatory milestone.
The vesting schedule of the CEO's stock awards aligns her interests with those of the shareholders, as the awards vest over time contingent on her continued service to the company.

Insider Trading Filed: 2026-01-07

Key Insights

Karimah Es Sabar, a director of Capricor Therapeutics, acquired 15,500 stock options with an exercise price of $24.81, vesting over the course of 2026. This suggests continued confidence in the company's long-term prospects by an insider.
The option is subject to early exercise, allowing Sabar to purchase shares before they fully vest. This indicates a bullish view on the stock's future performance.
Sabar's option grant is part of annual board compensation, aligning her interests with those of Capricor's shareholders.

Insider Trading Filed: 2026-01-07

Key Insights

The reporting person, Philip J. Gotwals, has been granted a stock option to acquire 15,500 shares of Capricor Therapeutics, Inc. (CAPR) common stock. The option vests monthly over a one-year period, indicating the company's commitment to retaining its director.
The early exercise feature of the stock option allows the reporting person to purchase shares prior to vesting, which could signal confidence in the company's long-term prospects.
The reporting person's direct ownership of the stock option represents a meaningful financial stake in the company, potentially aligning his interests with those of other shareholders.

Insider Trading Filed: 2026-01-07

Key Insights

Insider Paul Gisbert Auwaerter acquired 22,280 stock options with an exercise price of $24.81, vesting over time and immediately exercisable, indicating positive long-term outlook.
The options acquired include 15,500 shares for annual board service, 1,360 shares for board committee service, and 5,420 shares for additional board service, suggesting the company is rewarding and incentivizing the director.
The immediate exercisability of the options allows the director to rapidly increase their ownership stake, potentially signaling confidence in the company's future performance.

Insider Trading Filed: 2026-01-07

Key Insights

Insider Karen Krasney, EVP and General Counsel, acquired 45,000 stock options with an exercise price of $24.81, indicating potential confidence in the company's future prospects.
The stock options vest in two tranches - 22,500 shares vest over time and 22,500 shares vest upon FDA approval of the company's drug Deramiocel, suggesting important milestones ahead.
The significant insider purchase of options suggests Krasney believes the company's stock is undervalued and has upside potential.

Insider Trading Filed: 2026-01-07

Key Insights

Insider Anthony Bergmann, the Chief Financial Officer, has been granted 25,000 stock options with a strike price of $24.81 that will vest over 10 years, and 2,500 restricted stock units that will vest over 4 years, indicating potential alignment of his interests with those of shareholders.
The options granted on January 5, 2026 are subject to early exercise, allowing the reporting person to exercise the options and acquire the underlying shares prior to vesting, which could signal confidence in the company's future performance.
The vesting of a separate tranche of 25,000 stock options is tied to the FDA approval of the company's drug candidate Deramiocel, potentially linking the reporting person's compensation to the achievement of a key clinical milestone.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information